COVID-19 Vaccine Acceptance in Azuay Province, Ecuador: A Cross-Sectional Online Survey.
COVID-9
Ecuador
hesitancy
vaccine acceptance
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
21 Jun 2021
21 Jun 2021
Historique:
received:
24
04
2021
revised:
16
06
2021
accepted:
16
06
2021
entrez:
2
7
2021
pubmed:
3
7
2021
medline:
3
7
2021
Statut:
epublish
Résumé
We investigated the COVID-19 vaccination acceptance level in Azuay province, Ecuador through an online survey from 12th to 26th February (before the start of the COVID-19 vaccination campaign in Ecuador). Overall, 1219 respondents participated in the survey. The mean age was 32 ± 13 years; 693 participants (57%) were female. In total, 1109 (91%) of the participants indicated they were willing to be vaccinated with a COVID-19 vaccine, if the vaccine is at least 95% effective; 835 (68.5%) if it is 90% effective and 493 (40.5%) if it is 70% effective; 676 (55.5%) participants indicated they feared side effects and 237 (19.4%) thought the vaccine was not effective. Older age, having had a postgraduate education, a history of a negative COVID-19 test, a high level of worry of contracting COVID-19, believing that COVID-19 infection can be prevented with a vaccine and understanding there is currently an effective vaccine against COVID-19 were associated with higher vaccination acceptance. A vaccination education campaign will be needed to increase the knowledge of Ecuadorians about the COVID-19 vaccine and to increase their trust in the vaccine. People with a lower education level and living in rural areas may need to be targeted during such a campaign.
Identifiants
pubmed: 34205483
pii: vaccines9060678
doi: 10.3390/vaccines9060678
pmc: PMC8235423
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : VLIRUOS (Flemish University development aid
ID : 36-7921
Références
Int J Environ Res Public Health. 2020 Aug 13;17(16):
pubmed: 32823775
Hum Vaccin Immunother. 2020 Nov 1;16(11):2604-2608
pubmed: 32703069
JAMA. 2020 Jun 23;323(24):2458-2459
pubmed: 32421155
Vaccine. 2020 Dec 3;38(51):8090-8098
pubmed: 33187765
J Health Psychol. 2010 Apr;15(3):446-55
pubmed: 20348365
Cell. 2020 Apr 16;181(2):281-292.e6
pubmed: 32155444
Vaccine. 2020 Jan 16;38(3):470-481
pubmed: 31767469
Vaccine. 2015 Aug 14;33(34):4161-4
pubmed: 25896383
Vaccines (Basel). 2021 May 17;9(5):
pubmed: 34067682
JAMA Netw Open. 2020 Oct 1;3(10):e2025594
pubmed: 33079199
N Engl J Med. 2021 Jun 3;384(22):2092-2101
pubmed: 33835769
Glob Public Health. 2022 Jun;17(6):1087-1098
pubmed: 33843459
Vaccine. 2021 Jan 8;39(2):247-254
pubmed: 33328140
Vaccine. 2016 Feb 17;34(8):1018-24
pubmed: 26672676
Nat Med. 2021 Feb;27(2):225-228
pubmed: 33082575
PLoS One. 2018 Dec 7;13(12):e0208601
pubmed: 30532274
Vaccines (Basel). 2020 Aug 27;8(3):
pubmed: 32867224
Vaccine. 2015 May 21;33(22):2530-5
pubmed: 25869886
BMJ. 2020 Jun 4;369:m2184
pubmed: 32499217
Proc Natl Acad Sci U S A. 2021 Mar 9;118(10):
pubmed: 33619178
Lancet. 2021 Mar 13;397(10278):1023-1034
pubmed: 33587887
Commun Med (Lond). 2021 Jul 16;1:16
pubmed: 35602197
Health Expect. 2020 Dec;23(6):1543-1578
pubmed: 33022806